Research Highlight |
Featured
-
-
Review Article |
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective
In this Review, the authors discuss the potential causes of the heterogeneity of COVID-19 and summarize the pathobiology of the disease, with an emphasis on the role of the pulmonary vasculature in the acute stage and the potential for developing chronic pulmonary hypertension.
- Sarah Halawa
- , Soni S. Pullamsetti
- & Magdi H. Yacoub
-
Perspective |
Cardiac involvement in the long-term implications of COVID-19
In this Perspectives article, the authors highlight what is known about cardiovascular sequelae in survivors of COVID-19 and discuss important questions that need to be addressed in prospective studies to understand and mitigate these lasting cardiovascular consequences, including in post-acute COVID-19 syndrome.
- Benjamin A. Satterfield
- , Deepak L. Bhatt
- & Bernard J. Gersh
-
Research Highlight |
Social disparities in COVID-19 prevention
Patients with cardiovascular disease who live with socioeconomic disadvantage face barriers to healthy living. A new study assessing social disadvantage burden reveals that this patient population has poor adherence to COVID-19 risk-mitigation recommendations.
- Ciarán Martin Fitzpatrick
-
-
-
Research Highlight |
ACEi reduces hypertension-induced hyperinflammation in COVID-19
Antihypertensive therapy, particularly with the use of an angiotensin-converting enzyme inhibitor, improves outcomes in patients with hypertension and SARS-CoV-2 infection, who are susceptible to hyperinflammation and severe outcomes with COVID-19.
- Gregory B. Lim
-
Review Article |
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
This Review summarizes the latest evidence indicating that platelet and endothelial dysfunction are essential components of COVID-19 pathology, describes the potential mechanisms underlying the contribution of cardiovascular risk factors to the most severe outcomes in COVID-19, and highlights the roles of coagulopathy, thrombocytopathy and endotheliopathy in COVID-19 pathogenesis.
- Sean X. Gu
- , Tarun Tyagi
- & John Hwa
-
Review Article |
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
In this Review, Tschöpe and colleagues summarize and evaluate the available evidence on the pathogenesis, diagnosis and treatment of myocarditis and inflammatory cardiomyopathy, with special focus on virus-induced and virus-associated myocarditis. The authors also identify knowledge gaps, appraise available experimental models and propose future directions for the field.
- Carsten Tschöpe
- , Enrico Ammirati
- & Sophie Van Linthout
-
Comment |
The COVID-19 pandemic: a catalyst to improve clinical trials
The COVID-19 pandemic has provided the vital stepping stones to improve how clinical trials are conducted. We provide an overview of the major changes to the clinical trial process instigated by the pandemic and suggest ways to make these changes sustainable.
- Prakriti Gaba
- & Deepak L. Bhatt
-
Review Article |
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
The presence of cardiovascular comorbidities is linked with worse outcomes in patients with coronavirus disease 2019 (COVID-19), and COVID-19 can induce cardiovascular damage. In this Review, Wu and colleagues summarize the latest mechanistic and clinical studies that contribute to our current understanding of COVID-19-related cardiovascular disease.
- Masataka Nishiga
- , Dao Wen Wang
- & Joseph C. Wu
-
Research Highlight |
Reduced hospital admissions for ACS — more collateral damage from COVID-19
A decline in the number of hospital admissions for acute coronary syndrome was observed across Italy and USA during the peak of the COVID-19 pandemic.
- Karina Huynh
-
Research Highlight |
Myocardial injury in patients with COVID-19
In patients with COVID-19, myocardial injury is prevalent and is associated with an adverse prognosis and increased mortality, according to two retrospective cohort studies from China and the USA.
- Gregory B. Lim
-
Research Highlight |
RAAS inhibitors do not increase the risk of COVID-19
According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.
- Irene Fernández-Ruiz
Browse broader subjects
Browse narrower subjects
- Adenovirus
- Alphaviruses
- Antivirals
- Arenaviruses
- Dengue virus
- Ebola virus
- Hepatitis B virus
- Hepatitis C virus
- Herpes virus
- HTLV
- Human papilloma virus
- Influenza virus
- Marburg virus
- Measles virus
- Metagenomics
- Phage biology
- Pox virus
- Restriction factors
- Retrovirus
- Rotavirus
- SARS-CoV-2
- SARS virus
- Viral epidemiology
- Viral evolution
- Viral host response
- Viral immune evasion
- Viral membrane fusion
- Viral pathogenesis
- Viral reservoirs
- Systems virology
- Viral transmission
- Viral vectors
- Virus–host interactions
- Virus structures
- West nile virus